New Leaf Venture Partners
VC Fund
New York, United States
New Leaf Venture Partners is a venture capital firm that invests primarily in healthcare technology. The company typically focuses on later stage biopharmaceutical products, early stage medical devices, and laboratory infrastructure technologies.The New Leaf Ventures (NLV) team has been built over a decade, originating within Sprout Group, theventure capital affiliate of Credit Suisse First Boston. Sprout Group was formed in 1969 and has historically been one of the leading venture capital firms in the country. The team started to invest in healthcare technology in 1993 and since then, has become a leading venture investor in that sector. In 2005, the entire healthcare technology team of Sprout spun out into NLV.
- Total investments:
- 164
- Last investment:
- Lead investor:
- 24%
- Fund size:
- $17M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries New Leaf Venture Partners invests in
Stages New Leaf Venture Partners invests in
Countries New Leaf Venture Partners invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $10M–$65M
- Series B
- $10M–$84M
- Series C
- $20M–$101M
Investment Focus
Industry
- Health Care 70 (43%)
- Biotechnology 60 (37%)
- Medical 35 (21%)
- Pharmaceutical 25 (15%)
- Therapeutics 22 (13%)
Stage
- Series B 36 (22%)
- Series C 29 (18%)
- Series A 22 (13%)
- Funding Round 14 (9%)
- Series D 12 (7%)
Country
- United States 80 (49%)
- United Kingdom 4 (2%)
- Canada 2 (1%)
- Switzerland 2 (1%)
- Israel 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Craig Slutzkin
CFO & COO
|
CFO & COO | Total investments: 0 | Find email | |
James Niedel
Managing Director
|
Managing Director | Total investments: 8 | Find email | |
Liam Ratcliffe
Managing Director
|
Managing Director | Total investments: 17 | Find email | |
Ronald Hunt
Managing Director
|
Managing Director | Total investments: 6 | Find email | |
Vijay Lathi
Managing Director
|
Managing Director | Total investments: 31 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both autoimmunity and cancer. They leverage the systematic target validation and clinical insights gained by its founders to identify new targets. Their intensive use of bioinformatics to interrogate the transcriptome of human disease together with ex-vivovalidation in diseased tissue has uncovered new approaches to target key compartments of the immune system.The company was incorporated in 2015 and is based in Newton, Massachusetts. | $66M / Series D / Aug 18, 2026 | ||
| BrightInsight provides a digital health platform for bio-pharma and med-tech. Its IoT platform is built under a quality management system to support and optimize regulated drugs, devices, and software through integrated data and actionable insights to enable customers to drive increased patient adherence and engagement. BrightInsight was foundedin 2017 and is headquartered in San Jose, California. | $13M / Venture - Series Unknown / Jan 20, 2026 | ||
| Electra Therapeutics is a clinical stage biotechnology company developing therapies for cancer and other immunological diseases. | $183M / Series C / Oct 22, 2025 | ||
| Star Therapeutics mission is to develop therapies for as many diseases as possible for millions of patients. | $125M / Series D / Sep 30, 2025 | ||
| Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both autoimmunity and cancer. They leverage the systematic target validation and clinical insights gained by its founders to identify new targets. Their intensive use of bioinformatics to interrogate the transcriptome of human disease together with ex-vivovalidation in diseased tissue has uncovered new approaches to target key compartments of the immune system.The company was incorporated in 2015 and is based in Newton, Massachusetts. | $200M / Series C / Feb 12, 2025 | ||
| Kalderos is the creator of a drug discount management solution. It provides a SaaS-based drug discount management solution, which identifies, checks, and resolves non-compliance. Using models and machine learning processes, Kalderos detects inconsistencies overlooked by current methods, providing material benefits by eliminating waste. It wasfounded in 2016 and is headquartered in Chicago, Illinois. | $26.4M / Venture - Series Unknown / Jan 03, 2025 | ||
| Sunbird Bio is a diagnostics platform developer that aims to give molecular diagnostics with faster outcomes. Sunbird Bio was founded by Huilin Shao. | $14M / Venture - Series Unknown / Oct 16, 2024 | ||
| Windup Minds is a game studio focused on creating VR and MR virtual pet experiences. The company runs a gaming studio that aims to bring virtual pet games to market. | Pre-Seed / Oct 15, 2024 | ||
| Truveris brings transparency to the prescription drug ecosystem through data-driven innovations. Truveris’ platform offers customers – from the individual patient to employers, retailers, pharmacy benefits stakeholders, and manufacturers – the data and insights they need to effectively and efficiently manage rising costs and market accesschallenges.Based in Manhattan, Truveris is backed by Canaan Partners, New Leaf Venture Partners, Tribeca Venture Partners, New Atlantic Ventures and First Round Capital. | $15M / Series E / May 14, 2024 | ||
| Qlaris Bio focuses on developing novel and innovative therapies for serious and debilitating ophthalmic diseases. Qlaris Bio is a spinout company of Qrativ, a biotechnology incubator formed as a joint venture between Mayo Clinic and inference, a pharmaceutical-focused artificial intelligence company. Its lead program is QLS-101, a novel compoundinvented at Mayo Clinic and the University of Minnesota. QLS-101, with its unique and first-in-class mechanism of action, may potentially serve as an efficacious treatment for high unmet need conditions related to disturbances in intraocular pressure, including a sight-threatening and progressive Pediatric Rare Disease for which effective therapies remain elusive and limited.Qlaris Bio was founded in 2019 and is headquartered in Cambridge, Massachusetts. | $24M / Series B / Apr 22, 2024 | ||
| See all 164 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does New Leaf Venture Partners invest in?
New Leaf Venture Partners invests primarily in Health Care, Biotechnology and Medical startups, most often at Series B and Series C stage. Most of the 164 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is New Leaf Venture Partners's check size?
New Leaf Venture Partners typically joins rounds of $10M–$65M at Series A, $10M–$84M at Series B and $20M–$101M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds New Leaf Venture Partners participates in.
How do I contact New Leaf Venture Partners?
Public channels for New Leaf Venture Partners include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at New Leaf Venture Partners?
The team at New Leaf Venture Partners includes Craig Slutzkin (CFO & COO), James Niedel (Managing Director) and Liam Ratcliffe (Managing Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
